|
[1]
|
Goldberg, S.L., Chen, E., Corral, M., et al. (2010) Incidence and Clinical Complications of Myelodysplastic Syndromes among United States Medicare Beneficiaries. Journal of Clinical Oncology, 28, 2847-2852. [Google Scholar] [CrossRef]
|
|
[2]
|
Rebulla, P. (2005) A Mini-Review on Platelet Refractoriness. Haematologica, 90, 247-253.
|
|
[3]
|
Kaushansky, K. (2005) The Molecular Mechanisms That Control Thrombopoiesis. The Journal of Clinical Investigation, 115, 3339-3347. [Google Scholar] [CrossRef]
|
|
[4]
|
Mitchell, W.B. and Bussel, J.B. (2015) Thrombopoietin Re-ceptor Agonists: A Critical Review. Seminars in Hematology, 52, 46-52. [Google Scholar] [CrossRef]
|
|
[5]
|
Xie, C., Zhao, H., Bao, X., Fu, H. and Lou, L. (2018) Phar-macological Characterization of Hetrombopag, a Novel Orally Active Human thrombopoietin Receptor Agonist. Journal of Cellular and Molecular Medicine, 22, 5367-5377. [Google Scholar] [CrossRef]
|
|
[6]
|
Mei, H., Chen, X., Zhou, J., et al. (2022) Safety and Efficacy of Hetrombopag in Patients with Chronic Immune Thrombocytopenia: A Single-Arm, Open-Label, Multi-Center Phase 1 Study. Annals of Translational Medicine, 10, Article No. 30. [Google Scholar] [CrossRef]
|
|
[7]
|
Terrault, N., Chen, Y.C., Izumi, N., et al. (2018) Avatrom-bopag before Procedures Reduces Need for Platelet Transfusion in Patients with Chronic Liver Disease and Thrombocy-topenia. Gastroenterology, 155, 705-718. [Google Scholar] [CrossRef]
|
|
[8]
|
Al-Samkari, H., Jiang, D., Gernsheimer, T., et al. (2022) Adults with Immune Thrombocytopenia Who Switched to Avatrombopag Following Prior Treatment with Eltrombopag or Romiplostim: A Multicentre US Study. British Journal of Haematology, 197, 359-366. [Google Scholar] [CrossRef]
|
|
[9]
|
Oliva, E.N., Alati, C., Santini, V., et al. (2017) Eltrombopag versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Phase 1 Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial. The Lancet Haematology, 4, e127-e136. [Google Scholar] [CrossRef]
|
|
[10]
|
Mittelman, M., Platzbecker, U., Afanasyev, B., et al. (2018) Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukaemia and Severe Thrombocytopenia (ASPIRE): A Randomised, Placebo-Controlled, Phase 2 Trial. The Lancet Haematology, 5, e34-e43. [Google Scholar] [CrossRef]
|
|
[11]
|
Platzbecker, U., Wong, R.S., Verma, A., et al. (2015) Safety and Tolerability of Eltrombopag versus Placebo for Treatment of Thrombocytopenia in Patients with Advanced Myelo-dysplastic Syndromes or Acute Myeloid Leukaemia: A Multicentre, Randomised, Placebo-Controlled, Double-Blind, Phase 1/2 Trial. The Lancet Haematology, 2, e417-e426. [Google Scholar] [CrossRef]
|
|
[12]
|
Nomoto, M., Pastino, G., Rege, B., et al. (2018) Pharmaco-kinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects. Clinical Pharmacology in Drug Development, 7, 188-195. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Al-Samkari, H. (2018) Avatrombopag Maleate for the Treatment of Peripro-cedural Thrombocytopenia in Patients with Chronic Liver Disease. Drugs of Today, 54, 647-655. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Peng, G., He, G., Chang, H., et al. (2022) A Multicenter Phase II Study on the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia Refractory to Immunosup-pressive Therapy. Therapeutic Advances in Hematology, 13. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Duong, V.H., Al Ali, N., Zhang, L., et al. (2020) A Sequential Two-Stage Dose Escalation Study of Eltrombopag in Patients with Myelodysplastic Syndrome and Thrombocytopenia after Hypomethylating Agent Failure. Leukemia & Lymphoma, 61, 1901-1907. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Svensson, T., Chowdhury, O., Garelius, H., et al. (2014) A Pilot Phase I Dose Finding Safety Study of the Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients with Myel-odysplastic Syndrome Treated with Azacitidine. European Journal of Haematology, 93, 439-445. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Brynes, R.K., Orazi, A., Theodore, D., et al. (2015) Evaluation of Bone Marrow Reticulin in Patients with Chronic Immune Thrombocytopenia Treated with Eltrombopag: Data from the EXTEND Study. American Journal of Hematology, 90, 598-601. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Vlachodimitropoulou, E., Chen, Y.L., Garbowski, M., et al. (2017) Eltrom-bopag: A Powerful Chelator of Cellular or Extracellular Iron(III) Alone or Combined with a Second Chelator. Blood, 130, 1923-1933. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Yang, W., Zhao, X., He, G., et al. (2022) Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study. Annals of Hematology, 101, 2611-2616. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Fukushima-Shintani, M., Suzuki, K., Iwatsuki, Y., et al. (2008) AKR-501 (YM477) in Combination with Thrombopoietin Enhances Human Megakaryocytopoiesis. Experimental He-matology, 36, 1337-1342. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Yang, G., Huang, R., Yang, S., et al. (2020) Effect of Postdose Fasting Duration on Hetrombopag Olamine Pharmacokinetics and Pharmacodynamics in Healthy Volunteers. British Journal of Clinical Pharmacology, 86, 1528-1536. [Google Scholar] [CrossRef] [PubMed]
|